EXPRESSION OF ROTAVIRUS OUTER CAPSID PROTEIN VP4 BY RECOMBINANT ADENOVIRUS

轮状病毒是婴幼儿严重腹泻的主要原因 发达国家和发展中国家的儿童。 因此，密集 目前正在努力研制有效的疫苗。 两个外衣壳 轮状病毒蛋白VP7或VP4各自与诱导 中和抗体在实验动物中被证明是 与抵抗疾病有关。 血清型特异性已被 与VP7有关。 然而，最近的研究已经开始阐明 轮状病毒的抗原关系 VP4蛋白的特异性。 人轮状病毒株， 与症状性感染相关，表现出VP7特异性， 血清型1、2、3、4或9各自具有相似的VP4，如通过 中和试验 我们选择了猪轮状病毒OSU的外壳蛋白VP4， 模型来研究该蛋白在腺病毒载体中的免疫原性。 腺病毒口服给药的能力使其潜在的用途 用于疫苗生产的腺病毒载体特别有吸引力。 在 此外，腺病毒疫苗已被证明对人类是安全的 当作为肠溶包衣胶囊或片剂口服给药时。

Rotaviruses are the major cause of severe diarrhea in infants and young children in both developed and developing countries. Therefore, intensive efforts are being made to develop an effective vaccine. Two outer capsid rotavirus proteins, VP7 or VP4, are each associated with the induction of neutralizing antibodies that have been shown in experimental animals to be associated with resistance to illness. Serotype specificity has been associated with VP7. However, recent studies have begun to elucidate the antigenic relationships among human rotaviruses based on the antigenic specificity of the VP4 protein as well. Human rotavirus strains that were associated with symptomatic infection and that exhibited VP7 specificity of serotype 1, 2, 3, 4, or 9 each possessed a similar VP4 as determined by neutralization assay. We have chosen the outer capsid protein VP4 of porcine rotavirus OSU as a model to study the immunogenicity of this protein in an adenovirus vector. The ability of adenovirus to be administered orally makes the potential use of adenovirus vectors for vaccine production particularly attractive. In addition, adenovirus vaccines have already been shown to be safe in humans when administered orally as enteric coated capsules or tablets.